BeiGene’s PD-1 Remains Solid In First Global Pivotal Study
Positive Interim Data In Later-Line NSCLC
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.
You may also be interested in...
The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.
Lilly is acquiring exclusive global rights to a Chinese domestically developed immuno-oncology drug in one of the year’s biggest commercial deals in the country.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.